Gaynitdinova, 46 patient N-acetylcysteine late treatment RCT: 15% shorter hospitalization [p=0.001] and 51% improved recovery [p=0.001] https://c19p.org/gaynitdinova
copied to clipboard
N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia
et al., Pulmonologiya, doi:10.18093/0869-0189-2021-31-1-21-29
RCT 46 hospitalized patients with moderate COVID-19 pneumonia, 24 treated wth N-acetylcysteine, showing significantly shorter hospitalization with treatment. NAC 1,200 – 1,500mg/day intravenously.
|
hospitalization time, 15.4% lower, relative time 0.85, p < 0.001, treatment 24, control 22.
|
|
relative improvement in lung Ct, 50.7% better, RR 0.49, p < 0.001, treatment 24, control 22.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Gaynitdinova et al., 2/19/2021, Randomized Controlled Trial, Russia, Europe, peer-reviewed, 6 authors, average treatment delay 7.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.